◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksO › OXB

Oxford Biomedica plc (OXB) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Oxford Biomedica plc (OXB) operates in the Biotechnology industry and is headquartered in Oxford, United Kingdom with about 977 employees. Its market capitalization is roughly £589 million. In the fiscal year ended 2025-12-31, OXB reported £169M in revenue and (£30M) in net income.

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Interactive charts & full statements →

OXB Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue£169M£129M£90M£140M
Gross Profit£66M£53M£40M£69M
Operating Income (EBIT)(£33M)(£44M)(£88M)(£52M)
Net Income(£30M)(£43M)(£158M)(£39M)

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OXB Free Cash Flow History

OXB Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets£326M£232M£252M£460M
Total Liabilities£234M£171M£174M£224M

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OXB viewer.

Other Companies in Biotechnology

← OWLTAll “O” companiesOXBR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.